Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MUHAMMAD Y SHEIKH

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1538194048
CMS profile
205977
Location
FRESNO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,075.60

51 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,747.30 24
Gilead Sciences, Inc. $237.71 22
AbbVie Inc. $66.41 4
Janssen Biotech, Inc. $24.18 1

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MUHAMMAD Y SHEIKH

NPI 1538194048 · CMS profile ID 205977

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

FRESNO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538194048?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MUHAMMAD Y SHEIKH, NPI 1538194048, CMS profile ID 205977. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538194048?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MUHAMMAD Y SHEIKH, NPI 1538194048, CMS profile ID 205977. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538194048?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MUHAMMAD Y SHEIKH, NPI 1538194048, CMS profile ID 205977, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1538194048?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

51 matching records · $2,075.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 51 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–51 of 51.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $14.1301/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848276971 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $50,924.72 114
PY2020 $4,160.97 10
PY2021 $2,075.60 51
PY2022 $6,897.44 14
PY2023 $1,990.52 41
PY2024 $16,991.38 47
PY2025 $3,365.23 46

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $634,624.22 80
PY2024 Principal investigator $325,903.71 119
PY2023 Principal investigator $804,443.69 26
PY2022 Recipient $394.00 1
PY2022 Principal investigator $281,058.30 18
PY2021 Recipient $242.50 1
PY2021 Principal investigator $430,703.83 23
PY2020 Recipient $2,927.79 1
PY2020 Principal investigator $970,923.26 43
PY2019 Recipient $2,537.89 1
PY2019 Principal investigator $730,770.05 43

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

80 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $915.38 12/17/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187888458
Principal investigator 1 Eli Lilly and Company $934.02 11/19/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187888456
Principal investigator 1 Bausch Health US, LLC $1,428.00 10/06/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840370
Principal investigator 1 Bausch Health US, LLC $1,428.00 10/06/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840374
Principal investigator 1 Bausch Health US, LLC $1,428.00 10/06/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840376
Principal investigator 1 Bausch Health US, LLC $2,337.00 09/03/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840213
Principal investigator 1 Bausch Health US, LLC $1,428.00 09/03/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840227
Principal investigator 1 Bausch Health US, LLC $2,337.00 09/03/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840240
Principal investigator 1 Bausch Health US, LLC $1,772.00 09/03/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840243
Principal investigator 1 Bausch Health US, LLC $2,337.00 09/03/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840255
Principal investigator 1 Bausch Health US, LLC $1,428.00 09/03/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840272
Principal investigator 1 Madrigal Pharmaceuticals $23,483.20 07/31/2025 Non-covered Recipient Entity
FRESNO CLINICAL RESEARCH CENTER
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247690
Principal investigator 1 Bausch Health US, LLC $423.00 07/23/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840210
Principal investigator 1 Bausch Health US, LLC $2,337.00 07/23/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840219
Principal investigator 1 Bausch Health US, LLC $1,392.00 07/23/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840222
Principal investigator 1 Bausch Health US, LLC $423.00 07/23/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840234
Principal investigator 1 Bausch Health US, LLC $1,428.00 07/23/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840246
Principal investigator 1 Bausch Health US, LLC $1,772.00 07/23/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840251
Principal investigator 1 Bausch Health US, LLC $1,772.00 07/23/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840279
Principal investigator 1 Bausch Health US, LLC $1,772.00 07/23/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840283
Principal investigator 1 Bausch Health US, LLC $423.00 07/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840238
Principal investigator 1 Bausch Health US, LLC $423.00 07/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840259
Principal investigator 1 Bausch Health US, LLC $2,337.00 07/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840264
Principal investigator 1 Bausch Health US, LLC $1,772.00 07/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840268
Principal investigator 1 Bausch Health US, LLC $1,670.00 07/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840276
Principal investigator 1 Madrigal Pharmaceuticals $69,980.10 06/16/2025 Non-covered Recipient Entity
FRESNO CLINICAL RESEARCH CENTER
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245685
Principal investigator 1 Madrigal Pharmaceuticals $2,784.06 06/12/2025 Non-covered Recipient Entity
FRESNO CLINICAL RESEARCH CENTER
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245557
Principal investigator 1 Madrigal Pharmaceuticals $8,264.56 06/12/2025 Non-covered Recipient Entity
FRESNO CLINICAL RESEARCH CENTER
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245561
Principal investigator 1 Bausch Health US, LLC $1,670.00 06/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840287
Principal investigator 1 Bausch Health US, LLC $1,670.00 06/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840291
Principal investigator 1 Bausch Health US, LLC $1,670.00 06/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840311
Principal investigator 1 Bausch Health US, LLC $423.00 06/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840314
Principal investigator 1 Bausch Health US, LLC $423.00 06/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840320
Principal investigator 1 Bausch Health US, LLC $1,772.00 06/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840323
Principal investigator 1 Bausch Health US, LLC $423.00 06/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840327
Principal investigator 1 Bausch Health US, LLC $423.00 06/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840339
Principal investigator 1 Bausch Health US, LLC $423.00 06/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840361
Principal investigator 1 Bausch Health US, LLC $423.00 06/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840366
Principal investigator 1 Madrigal Pharmaceuticals $304,693.75 05/14/2025 Non-covered Recipient Entity
FRESNO CLINICAL RESEARCH CENTER
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243427
Principal investigator 1 Madrigal Pharmaceuticals $116,014.08 05/14/2025 Non-covered Recipient Entity
FRESNO CLINICAL RESEARCH CENTER
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243431
Principal investigator 1 Bausch Health US, LLC $1,740.00 05/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840343
Principal investigator 1 Bausch Health US, LLC $1,670.00 05/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840350
Principal investigator 1 Bausch Health US, LLC $1,670.00 05/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840354
Principal investigator 1 Bausch Health US, LLC $423.00 04/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840295
Principal investigator 1 Bausch Health US, LLC $423.00 04/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840299
Principal investigator 1 Bausch Health US, LLC $423.00 04/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840303
Principal investigator 1 Bausch Health US, LLC $1,740.00 04/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840307
Principal investigator 1 Bausch Health US, LLC $423.00 04/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840332
Principal investigator 1 Bausch Health US, LLC $2,337.00 04/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840335
Principal investigator 1 Bausch Health US, LLC $1,740.00 04/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840347
Principal investigator 1 Bausch Health US, LLC $1,740.00 04/02/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840358
Principal investigator 1 Madrigal Pharmaceuticals $6,479.37 04/01/2025 Non-covered Recipient Entity
FRESNO CLINICAL RESEARCH CENTER
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248241509
Principal investigator 1 Bausch Health US, LLC $1,670.00 03/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840102
Principal investigator 1 Bausch Health US, LLC $423.00 03/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840113
Principal investigator 1 Bausch Health US, LLC $1,740.00 03/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840126
Principal investigator 1 Bausch Health US, LLC $1,428.00 03/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840136
Principal investigator 1 Bausch Health US, LLC $1,428.00 03/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840178
Principal investigator 1 Bausch Health US, LLC $423.00 03/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840201
Principal investigator 1 Madrigal Pharmaceuticals $9,025.65 02/17/2025 Non-covered Recipient Entity
FRESNO CLINICAL RESEARCH CENTER
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248239793
Principal investigator 1 Bausch Health US, LLC $1,740.00 02/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840108
Principal investigator 1 Bausch Health US, LLC $423.00 02/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840144
Principal investigator 1 Bausch Health US, LLC $423.00 02/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840148
Principal investigator 1 Bausch Health US, LLC $1,670.00 02/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840160
Principal investigator 1 Bausch Health US, LLC $1,670.00 02/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840172
Principal investigator 1 Bausch Health US, LLC $1,670.00 02/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840183
Principal investigator 1 Bausch Health US, LLC $2,337.00 02/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840187
Principal investigator 1 Bausch Health US, LLC $423.00 02/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840190
Principal investigator 1 Bausch Health US, LLC $423.00 02/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840204
Principal investigator 1 Bausch Health US, LLC $2,337.00 02/07/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840206
Principal investigator 1 Madrigal Pharmaceuticals $1,518.75 02/07/2025 Non-covered Recipient Entity
FRESNO CLINICAL RESEARCH CENTER
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248239581
Principal investigator 1 Madrigal Pharmaceuticals $2,369.30 01/09/2025 Non-covered Recipient Entity
FRESNO CLINICAL RESEARCH CENTER
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248238124
Principal investigator 1 Bausch Health US, LLC $1,772.00 01/08/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840118
Principal investigator 1 Bausch Health US, LLC $1,670.00 01/08/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840122
Principal investigator 1 Bausch Health US, LLC $423.00 01/08/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840130
Principal investigator 1 Bausch Health US, LLC $1,842.00 01/08/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840141
Principal investigator 1 Bausch Health US, LLC $1,772.00 01/08/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840151
Principal investigator 1 Bausch Health US, LLC $423.00 01/08/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840156
Principal investigator 1 Bausch Health US, LLC $423.00 01/08/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840164
Principal investigator 1 Bausch Health US, LLC $423.00 01/08/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840168
Principal investigator 1 Bausch Health US, LLC $1,670.00 01/08/2025 Non-covered Recipient Entity
Fresno Clincal Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840197